Mitsubishi Motor Sales of Canada announces an innovative AI-powered tool designed to transform the customer experience for ...

Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca’s (AZN) WAINZUA eplontersen has been approved in the European Union EU for ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis and AstraZeneca’s WAINZUA (eplontersen) has been approved in the European Union (EU ...

Ionis Pharmaceuticals IONS announced that the European Commission (“EC”) has approved Wainzua (eplontersen) for treating adult patients with hereditary transthyretin-mediated amyloidosis with ...

(RTTNews) - Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca's WAINZUA has been approved in the European Union for the treatment of hereditary transthyretin-mediated amyloidosis ...

AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be marketed as Wainzua (eplontersen). The drug has been approved to treat ...

Ionis Pharmaceuticals IONS announced that the European Commission (“EC”) has approved Wainzua (eplontersen) for treating adult patients with hereditary transthyretin-mediated amyloidosis with stage 1 ...

AstraZeneca and Ionis Pharma have an EU green light for their Wainzua therapy for hereditary transthyretin-mediated amyloidosis (ATTR) polyneuropathy, building on earlier approvals in the US and ...

Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with polyneuropathy associated with transthyretin ...